2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Profiling, Treatment Considerations, Biological Therapies, Transplantation, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, Study Population, Human, Adult
PAPER

1719 Pre-transplant measurable residual disease assessed by ultra-high sensitivity next-generation sequencing predicts outcomes after allogeneic stem cell transplantation in young adults with acute myeloid leukemia

Nicolas Duployez, MD, Anne Huynh, MD2, Augustin Boudry3, Sylvain Chantepie, MD4, Alice Marceau-Renaut5, Martin Carre, MD6, Lucie Rigolot, MD7, Jean Baptiste Mear, MD8, Marie Robin, MD9, Mathieu Leclerc, PhD10, Pascal Turlure11, Chama Mokeddem, MD12, Jean-Valère Malfuson, MD13, Ibrahim Yakoub-Agha, MD, PhD14, Michael Loschi, MD, PhD15, Jean-Henri Bourhis, MD, PhD16, Bruno Lioure, MD17, Anne Menard18, Delphine Lebon, MD, PhD19, Patrice Chevallier, MD, PhD20, Natacha Maillard21, Raynier Devillier, PhD22, Nicole Raus23, Maxime Bucci24, Sandrine Geffroy25, Arnaud Pigneux, MD, PhD26, Hunault-Berger Mathilde, MD, PhD27, Norbert Ifrah, PR28, Christian Recher, MD, PhD29, Herve Dombret Sr, MD30, Gerard Socie, MD, PhD31, Jean-Yves Cahn, MD32, Eric Delabesse33, Regis Peffault De Latour, MD, PhD34, Claude Preudhomme, PhD35, Edouard Forcade, MD, PhD36
1 CHU Lille, Lille, France
2 Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
3 CHU Lille, Lille, France
4 CHU de Caen, Caen, France
5 CHU Lille, Lille, France
6 CHU de Grenoble, Grenoble, France
7 Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
8 CHU de Rennes, Rennes, France
9 Hôpital Saint Louis, AP-HP, Paris, France
10 Hôpital Henri Mondor, AP-HP, Créteil, France
11 CHU de Limoges, Limoges, France
12 CHU d'Angers, Angers, France
13 Centre des armées Percy, Clamart, France
14 CHU Lille, Lille, France
15 CHU de Nice, Nice, France
16 Institut Gustave Roussy, Villejuif, France
17 CHU de Strasbourg, Strasbourg, France
18 Centre Henri Becquerel, Rouen, France
19 CHU d'Amiens, Amiens, France
20 CHU de Nantes, Nantes, France
21 CHU de Poitiers, Poitiers, France
22 Institut Paoli-Calmettes, Marseille, France
23 Hôpital Lyon Sud, Lyon, France
24 CHU Lille, Lille, France
25 CHU Lille, Lille, France
26 CHU de Bordeaux, Bordeaux, France
27 CHU d'Angers, Angers, France
28 CHU d'Angers, Angers, France
29 Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
30 Hôpital Saint Louis, AP-HP, Paris, France
31 Hôpital Saint Louis, AP-HP, Paris, France
32 CHU de Grenoble, Grenoble, France
33 Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
34 Hôpital Saint Louis, AP-HP, Paris, France
35 CHU Lille, Lille, France
36 CHU de Bordeaux, Bordeaux, France

Background: Measurable residual disease (MRD) is a major determinant of outcome in acute myeloid leukemia (AML). We evaluated the prognostic impact of pre-transplant MRD assessed by ultrahigh-sensitivity next-generation sequencing (UHS-NGS) in a large prospective cohort of younger adults with AML treated with intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1).

Methods: Adult patients aged 18–60 years with newly diagnosed AML enrolled between 01/2015 and 07/2021 in the BIG-1 trial (NCT02416388) and undergoing allo-HSCT in CR1 were retrospectively analyzed. Transplantation strategies were risk-adapted according to baseline genetic features, treatment response, and transplant-related risk. MRD in pre-transplant bone marrow (BM) was assessed using a 32-gene capture-based UHS-NGS assay with a limit of detection (LOD) of 10^-4. MRD positivity was defined as the persistence of at least one leukemia-associated mutation above the assay LOD after exclusion of DNMT3A, TET2, ASXL1 (DTA), and IDH1/2 mutations. Among 353 transplanted patients with available pre-transplant BM DNA, 323 harbored at least one mutation covered by the panel. Patients harboring only DTA and/or IDH1/2 mutations at diagnosis were excluded for prognosis analyses, yielding a final study population of 296 patients.

Results: The likelihood of clonal persistence varied markedly according to the diagnostic mutation, ranging from 10% for FLT3 non-ITD mutations to 100% for UBTF-TD and exceeding 70% for DNMT3A, IDH2-R140, SRSF2, SF3B1, TP53, and TET2 mutations. Overall, 38.8% of non-DTA/non-IDH mutations remained detectable before transplantation, including 74.7% with a variant allele frequency (VAF) below 1%. Among the 296 evaluable patients, 164 (55.4%) had detectable pre-transplant MRD. Median age was 50.3 years, and 59.8% had adverse ELN 2022 risk. Patients with detectable pre-transplant MRD were older (52.6 vs 47.5 years, P<0.001), had lower BM blast infiltration at diagnosis (51.5% vs 68.0%, P=0.005) and more frequently harbored myelodysplasia-related gene mutations (56.7% vs 38.6%, P=0.002), and TP53 mutations (12.8% vs 4.5%, P=0.015).

With a median follow-up of 63.6 months, detectable pre-transplant MRD was independently associated with inferior overall survival (OS, adjusted HR 2.85, 95% CI 1.83-4.43, P<0.001), relapse-free survival (RFS, adjusted HR 2.58, 95% CI 1.72-3.87, P<0.001), and higher cumulative incidence of relapse (CIR, adjusted sHR 2.58, 95% CI 1.47-4.55, P=0.001) after multivariable adjustment for age, baseline genetic features, donor type and conditioning regimen.

Two-year OS, RFS, and CIR were 56.7%, 51.8%, and 23.2% in MRD-positive patients, compared with 81.0%, 78.0%, and 11.4%, respectively, in MRD-negative patients. Among MRD-positive patients, outcomes further worsened according to the number of persistent mutations, with two-year OS, RFS and CIR of 68.5% vs 42.7%, 64.0% vs 37.3%, and 16.9% vs 30.7% in patients harboring one versus ≥2 persistent mutations, respectively.

Persistent NPM1, FLT3-ITD, RUNX1, STAG2, and NRAS mutations showed the strongest adverse associations with post-transplant outcomes. Nevertheless, the prognostic contribution of individual mutations remained limited, and no single lesion fully accounted for the overall prognostic value of pre-transplant MRD.

Importantly, pre-transplant MRD remained independently associated with inferior OS (adjusted HR 2.29, 95% CI 1.30-4.01), inferior RFS (adjusted HR 2.14, 95% CI 1.28-3.59), and higher CIR (adjusted sHR, 2.45 95% CI 1.17-5.11) after exclusion of AML with NPM1 and/or FLT3-ITD mutations at diagnosis (N=198 patients).

Finally, among patients with positive MRD, myeloablative conditioning (MAC; median age 41y; 34.7% of the cohort) was associated with superior OS (P=0.045) and RFS (P=0.011), and a lower CIR (P=0.028) compared with reduced-intensity conditioning (RIC; median age 53y; 65.3%). In contrast, conditioning intensity did not significantly influence outcomes among MRD-negative patients (OS P=0.67, RFS P=0.92, CIR P=0.295).

Conclusions: Pre-transplant MRD assessed by UHS-NGS is a powerful predictor of relapse and survival in AML after allo-HSCT in CR1. Its prognostic value remains robust after exclusion of AML harboring established molecular MRD markers (i.e., NPM1 mutations and/or FLT3-ITD), supporting the broader applicability of UHS-NGS MRD assessment across AML molecular subtypes.

Nicolas Duployez, MD: Astellas - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony)